SCHEMBL20673889

SCHEMBL20673889

CS(=N)(=O)c1cn(O)c2ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AGTR1 P30556 3/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ FABP4 P15090 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HTR6 P50406 3/20 0.35
▸ MET P08581 1/20 0.34
▸ ERCC1 P07992 1/20 0.34
▸ FEN1 P39748 1/20 0.34
▸ ERCC4 Q92889 1/20 0.34
▸ FABP3 P05413 1/20 0.34
▸ FABP5 Q01469 1/20 0.34
▸ CCNT1 O60563 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20673901 0.86 AGTR1 (0.39) AGTR1KDM4EMEN1ALDH1A1MAPT
SCHEMBL20673909 0.79 LDHA (0.47) KDM4EALDH1A1FABP4HTR6FABP3
SCHEMBL20674170 0.78 FTO (0.43) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL20674168 0.74 COMT (0.39) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL20674167 0.71 EP300 (0.50) KDM4EKMT2AL3MBTL1
SCHEMBL20674532 0.68 POLB (0.34) AGTR1MEN1ALDH1A1MAPTKMT2A
SCHEMBL8927744 0.67 MEN1 (0.46) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL20674165 0.66 SMN1; SMN2 (0.55) MEN1ALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL19336961 0.66 L3MBTL1 (0.55) ALDH1A1MAPTKMT2AL3MBTL1POLB
SCHEMBL9654009 0.65 IDO1 (0.42) KDM4EMEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3399968-B1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS PHARMATECH LTD (KY) 2021-10-20 — — EP disclosed
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase CS PHARMATECH LIMITED (KY) 2019-10-08 — — US disclosed
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE HIGH GREAT INVESTMENT LIMITED (HK) 2019-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase EGFR, ERBB3, ERBB2 AGTR1 443/4885KDM4E 1867/4885MEN1 3422/4885
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 AGTR1 443/4885KDM4E 1867/4885MEN1 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback